Thomas John Van Blarcom

This inventor holds 26 USPTO granted patents and 25 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: Pfizer Corporation, Allogene Therapeutics, Inc., Allogene Therapeuctics, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas John Van Blarcom. Retrieved from https://idiyas.com/inventor/thomas-john-van-blarcom

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 25)

% Patents Active = 96.2

CIPO Patents = 1 (Patent Applications = 23)

EPO Patents = 5 (Patent Applications = 26)

Average Co-Inventor Count = 5.6

ph-index = 4

Forward Citations = 41(Granted Patents)

Company Filing History:

Allogene Therapeutics, Inc.

patents

1 out of 1

Allogene Therapeuctics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptors

Therapeutic Antibodies

T-Cell Modulation

Cytokine Receptors

CD70 Targeting

BCMA CAR-T Cells

Modified Caspase-9

Antibodies Specific for CD47

PD-L1

DLL3 Targeting

TGF Beta Binding Domains

Protease-Activating CD45-Gate CAR

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577290 - FASL EXPRESSION AND FASR GENE KNOCKOUT TO PROTECT THERAPEUTIC CELLS FROM ALLOGENEIC REJECTION AND ACTIVATION-INDUCED CELL DEATH (2026-03-17),

2. 12577283 - KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS (2026-03-17),

3. 12528856 - CHIMERIC CYTOKINE RECEPTORS COMPRISING TGF BETA BINDING DOMAINS (2026-01-20),

4. 12404315 - Protease-activating CD45-gate CAR (2025-09-02),

5. 12215347 - Chimeric antigen receptors with enhanced signaling and activities and uses thereof (2025-02-04),

6. 12163169 - Inducible chimeric cytokine receptors (2024-12-10),

7. 12152081 - Chimeric antigen receptors targeting CD70 (2024-11-26),

8. 12104188 - Modified caspase-9 polypeptides and methods of use thereof (2024-10-01),

9. 12043655 - Constitutively active chimeric cytokine receptors (2024-07-23),

10. 12036243 - BCMA CAR-T cells with enhanced activities (2024-07-16),

11. 11987634 - Antibodies specific for CD70 and their uses (2024-05-21),

12. 11912776 - Chimeric antigen receptors targeting B-cell maturation antigen (2024-02-27),

13. 11814435 - Therapeutic antibodies and their uses (2023-11-14),

14. 11786553 - Chimeric cytokine receptors bearing a PD-1 ectodomain (2023-10-17),

15. 11702474 - Antibodies specific for CD47, PD-L1, and uses thereof (2023-07-18),

Title: The Innovative Journey of Thomas John Van Blarcom

Introduction: Thomas John Van Blarcom, a talented inventor based in Oakland, CA, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Thomas John Van Blarcom holds several patents in various technological domains, including advancements in renewable energy systems, artificial intelligence algorithms, and sustainable transportation solutions.

Career Highlights: With a career spanning over two decades, Thomas John Van Blarcom has worked with leading tech companies to develop cutting-edge products that have revolutionized the industry. His expertise in engineering and design has led to the successful implementation of numerous projects.

Collaborations: Throughout his career, Thomas John Van Blarcom has collaborated with top researchers, engineers, and scientists to bring his ideas to life. His ability to work in multidisciplinary teams has resulted in the creation of innovative solutions that have had a lasting impact on society.

Conclusion: Thomas John Van Blarcom's passion for innovation and his dedication to pushing the boundaries of technology have established him as a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators.

Profile summary based on public USPTO records.